Filament Health signs LOI with Darmiyan to explore BrainSee AI in PEX010 early Alzheimer’s trial design

• Rhelion subsidiary Filament Health signed a non-binding LOI with Darmiyan to explore using BrainSee AI in PEX010 trial design.
• Work targets earlier identification, selection, monitoring of patients with amnestic mild cognitive impairment at higher five-year Alzheimer’s progression risk.
• Collaboration also evaluates Darmiyan’s voxel-based quantitative imaging outputs as exploratory measures of biological change in a future PEX010 study.
• BrainSee received FDA De Novo marketing authorization in January 2024 for prognosis in patients aged 55+ with amnestic mild cognitive impairment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608200739NEWSFILECNPR____20260820_310598_1) on August 20, 2026, and is solely responsible for the information contained therein.